CV Sciences Triples CBD Sales in Q2 to $12 .3 Million | CashCropToday
0 Shares 551 Views

CV Sciences Triples CBD Sales in Q2 to $12 .3 Million

July 25, 2018
551 Views

CV Sciences, Inc. (OTCQB: CVSI) announced this morning that the company’s second quarter 2018 revenue is expected to have reached $12.3 million, which is up 203% compared to their second quarter last year. The company owns the well-known hemp derived CBD product brand +CBD oil.

CV Sciences owns their own pharmaceutical drug division that works specifically on the research and development of commercial CBD Products. Their subsidiary +CBD Oil focused on the manufacturing, marketing, and distribution of Cannabidiol based products such as soft gel capsules, powdered capsules,  sublingual tinctures, topical and sprays.

In the announcement, CV Sciences indicated that the company has increased their retail store count to 1,968 organic health food stores as of the end of June 2018. By allowing customers to purchase online, as well as, through retail outlets across the country the company has been able to significantly increase its visibility with consumers.

CV Sciences, Inc. currently has a market cap of $234.82m and is trading at 2.769 per share.

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
278 views
Market Watch
278 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
196 views
Global
196 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
193 views
Manufacturing
193 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: